arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Immuneering Corporation

IMRX Health Care Biotechnology: Pharmaceutical Preparations
$4.87
▲ +1.0% Today
as of Sep 4, 16:50 ET
Last 30 days +10.55% Jul 27 → Sep 04
$3.95 $4.32 $4.69 $5.06 $5.43 Jul 27 Aug 04 Aug 12 Aug 19 Aug 27 Sep 04
Open
$4.94
High
$5.00
Low
$4.81
Volume
$999,737
Avg Vol
$1M
Mkt Cap
$340M
P/E (TTM)
—
Beta
—
52w High
$10.08
52w Low
$3.86
Div Yield
—
Shares Out
—

Recent Press Releases & News last 60 days · 6 items

Sep 3 · 20:05 PR GlobeNewswire
Immuneering to Participate in Upcoming Investor Conferences
Aug 26 · 21:16 PR GlobeNewswire
Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients
Aug 6 · 11:18 MT Newswires
HC Wainwright Initiates Immuneering at Buy With $14 Price Target
▸ Show all 6 press releases & news Free account →

Overview

52-week range
$3.86
$10
16% of range
Avg surprise (last 3)
+9.2%
Avg reaction (last 2)
+0.6%
100% positive
Latest IV / EM
46%
EM ±7.3% · $5 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.51$-0.43$-0.36$-0.28$-0.21 Actual $-0.51Actual $-0.43Actual $-0.43Actual $-0.49Actual $-0.47Actual $-0.49Actual $-0.42Est $-0.41Actual $-0.40Est $-0.40Actual $-0.38Actual $-0.21Est $-0.30Actual $-0.27 MarJunSepMarJunSepMar/2025Jun/2025SepMar/2026Jun
Revenue vs Net Income Revenue Net income
$-17M$-16M$-16M$-15M$-14M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.27 — — — — financials
Fri May 15, 2026Mar/2026 $-0.21 $-0.30 +30.0% +50.0% +0.4% earnings
Tue Sep 30, 2025Sep 2025 $-0.38 — — — — financials
Wed Aug 13, 2025Jun/2025 $-0.40 $-0.40 0.0% — — earnings
Mon May 5, 2025Mar/2025 $-0.42 $-0.41 -2.4% — +0.8% earnings
Mon Sep 30, 2024Sep 2024 $-0.49 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.47 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.49 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.43 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.43 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.51 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue————————
Cost of revenue————————
Gross profit————————
Operating income$-19M$-15M—$-15M$-15M$-15M—$-15M
Net income$-17M$-13M—$-15M$-14M$-15M—$-15M
EPS (diluted)$-0.27$-0.21—$-0.38$-0.40$-0.42—$-0.49

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$41M$47M$129M$228M$26M$36M$36M$45M
Inventory————————
Total current assets$158M$161M$176M$229M$28M$38M$40M$55M
Total assets$202M$215M$232M$241M$40M$51M$53M$69M
Long-term debt————————
Total liabilities$11M$8M$14M$13M$11M$9M$11M$11M
Total equity$191M$207M$218M$228M$29M$42M$41M$58M

Implied volatility — last 90 days

33%167%301%435%570% Jun 07 — IV 110% · EM ±15.2%Jun 08 — IV 568% · EM ±75.0%Jun 09 — IV 406% · EM ±50.9%Jun 10 — IV 475% · EM ±56.1%Jun 11 — IV 402% · EM ±44.4%Jun 12 — IV 408% · EM ±41.8%Jun 15 — IV 531% · EM ±38.4%Jun 16 — IV 503% · EM ±29.7%Jun 17 — IV 570% · EM ±23.8%Jun 19 — IV 113% · EM ±24.9%Jun 22 — IV 101% · EM ±21.2%Jun 23 — IV 132% · EM ±27.0%Jun 24 — IV 86% · EM ±17.3%Jun 25 — IV 87% · EM ±17.1%Jun 26 — IV 91% · EM ±17.4%Jun 29 — IV 75% · EM ±13.4%Jun 30 — IV 81% · EM ±14.0%Jul 01 — IV 86% · EM ±14.4%Jul 02 — IV 113% · EM ±18.3%Jul 03 — IV 117% · EM ±18.3%Jul 06 — IV 98% · EM ±13.6%Jul 07 — IV 78% · EM ±10.3%Jul 08 — IV 105% · EM ±13.1%Jul 09 — IV 107% · EM ±12.6%Jul 10 — IV 94% · EM ±10.4%Jul 13 — IV 75% · EM ±6.3%Jul 14 — IV 113% · EM ±8.2%Jul 15 — IV 139% · EM ±8.2%Jul 16 — IV 250% · EM ±10.4%Jul 20 — IV 187% · EM ±44.3%Jul 21 — IV 102% · EM ±23.8%Jul 22 — IV 132% · EM ±30.2%Jul 23 — IV 152% · EM ±34.2%Jul 24 — IV 107% · EM ±23.6%Jul 27 — IV 99% · EM ±20.6%Jul 28 — IV 92% · EM ±18.9%Jul 29 — IV 240% · EM ±48.1%Jul 30 — IV 113% · EM ±22.1%Jul 31 — IV 209% · EM ±40.0%Aug 03 — IV 237% · EM ±42.0%Aug 04 — IV 33% · EM ±5.7%Aug 05 — IV 123% · EM ±20.5%Aug 06 — IV 250% · EM ±40.4%Aug 10 — IV 191% · EM ±26.5%Aug 11 — IV 99% · EM ±13.0%Aug 12 — IV 71% · EM ±8.9%Aug 13 — IV 126% · EM ±14.9%Aug 14 — IV 107% · EM ±11.9%Aug 17 — IV 344% · EM ±28.7%Aug 19 — IV 286% · EM ±16.9%Aug 20 — IV 365% · EM ±15.2%Aug 24 — IV 83% · EM ±17.4%Aug 25 — IV 72% · EM ±14.8%Aug 26 — IV 70% · EM ±14.1%Aug 27 — IV 64% · EM ±12.5%Aug 28 — IV 75% · EM ±14.4%Aug 31 — IV 68% · EM ±12.0%Sep 01 — IV 60% · EM ±10.3%Sep 02 — IV 65% · EM ±10.8%Sep 03 — IV 55% · EM ±8.9%Sep 04 — IV 46% · EM ±7.3%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in